Moderna lifts 2026 outlook after quarterly revenue tops estimates
The company now expects revenue growth of 15% to 25%, citing momentum in newer products and stronger third-quarter results.
Key takeaways
- Moderna raised its 2026 revenue growth outlook to 15% to 25%.
- Third-quarter revenue reached $1.31 billion, above the $885.1 million analyst estimate.
Moderna raised its 2026 revenue growth outlook to 15% to 25%, from previous guidance of up to 10%, after third-quarter revenue and earnings beat analyst estimates.
The company reported $1.31 billion in revenue, compared with the $885.1 million expected by analysts surveyed by LSEG. Earnings were 38 cents per share, versus an expected loss of $1.25.
Revenue rose 29%, supported by higher Covid vaccine sales in international markets and deliveries under long-term government partnerships. Moderna reported $780 million in U.S. revenue and $533 million internationally.
CEO Stéphane Bancel said newer products and broader geographic reach helped drive the quarter. He said Moderna was seeing the full-year impact of its next-generation Covid vaccine, while its new stand-alone flu shot is expected to have a limited U.S. launch in 2026.
Moderna also reported net income of $162 million, compared with a net loss of $200 million in the year-earlier quarter. The results followed recent late-stage data from Moderna and Merck on their experimental personalized cancer vaccine with Keytruda in certain melanoma patients.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.
